Pharmaceutical Grade Cyclopropylboronic Acid Manufacturing Process: High-Yield Synthesis for API Intermediates
- Optimized low-temperature lithiation-hydrolysis route achieves >93% yield and ≥98% industrial purity. Key process controls minimize dicyclopropylboronic acid byproducts and ensure batch-to-batch reproducibility.
- NINGBO INNO PHARMCHEM CO.,LTD. offers bulk supply with full COA, NMR/HPLC validation, and cold-chain logistics.
Cyclopropylboronic Acid (CAS 411235-57-9) is a critical Suzuki Coupling Reagent widely employed in the synthesis of active pharmaceutical ingredients (APIs). Its strained cyclopropyl ring imparts unique metabolic stability and conformational rigidity, making it a privileged motif in modern drug design. As a high-value API Synthesis Intermediate, consistent access to material of verified industrial purity is essential for robust downstream coupling reactions. This article details the state-of-the-art manufacturing process used by leading global manufacturers to produce this sensitive organoboron compound.
Core Synthesis Route: Low-Temperature Lithiation & Controlled Hydrolysis
The most efficient and scalable synthesis route for pharmaceutical grade Cyclopropylboronic Acid leverages a two-step sequence starting from cyclopropyl bromide. This method, refined from established patent literature, overcomes the historical challenges of low yields (often 30–50%) associated with Grignard-based approaches.
The optimized process involves:
- Lithiation: Cyclopropyl bromide is reacted with sec-butyllithium (s-BuLi) or n-butyllithium (n-BuLi) in anhydrous tetrahydrofuran (THF) or diethyl ether at ultra-low temperatures (-78°C to -50°C). This stringent temperature control is critical to suppress self-coupling side reactions that plague higher-temperature protocols.
- Borylation & Hydrolysis: The generated cyclopropyllithium intermediate is then added to a solution of a boric acid ester—commonly triisopropyl borate or trimethyl borate—under the same cryogenic conditions. The resulting cyclopropylboronate ester is subsequently hydrolyzed using a mild acid (e.g., 1N HCl) to a pH of 3–4, liberating the free boronic acid.
This controlled approach consistently delivers Cyclopropylboronic Acid with a purity of ≥98% (as confirmed by quantitative 1H-NMR) and isolated yields exceeding 93%. The minimization of byproducts like dicyclopropylboronic acid is a direct result of the precise thermal management during the organometallic formation step.
ISO-Compliant Production Workflow for API Intermediates
For use in regulated pharmaceutical manufacturing, the entire production workflow must adhere to stringent quality standards. A premier global manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. implements a fully documented and validated process that includes:
- Dedicated, moisture-free reactors and handling systems to prevent decomposition of air- and moisture-sensitive intermediates.
- In-process controls (IPCs) at critical stages (e.g., post-lithiation, post-hydrolysis) to monitor reaction completion and impurity profiles.
- A multi-stage purification protocol involving extraction, concentration, and recrystallization from solvents like isopropyl ether or toluene to achieve the required industrial purity.
When sourcing high-purity Cyclopropylboronic Acid for GMP-compliant API synthesis, buyers should demand full traceability and documentation, including a comprehensive Certificate of Analysis (COA).
Analytical Validation: NMR, HPLC, and Residual Solvent Testing
Rigorous analytical testing is non-negotiable for any API Synthesis Intermediate. The final product specification typically includes the following validated methods:
| Test Parameter | Method | Acceptance Criteria |
|---|---|---|
| Assay / Purity | Quantitative 1H-NMR | ≥98.0% |
| Related Substances | Reversed-Phase HPLC | Any single impurity ≤0.5%; Total impurities ≤1.5% |
| Residual Solvents | GC (Headspace) | Meets ICH Q3C guidelines for Class 2/3 solvents (e.g., THF, MTBE) |
| Water Content | Karl Fischer Titration | ≤0.5% |
This comprehensive analytical package ensures the material’s suitability for sensitive cross-coupling reactions, where even trace impurities can significantly impact yield and selectivity.
Packaging and Cold-Chain Logistics for Bulk Shipments
Due to its sensitivity to moisture and potential for protodeboronation, (Cyclopropyl)boronic Acid requires specialized handling for bulk commercial supply. NINGBO INNO PHARMCHEM CO.,LTD., as a top-tier manufacturer, provides:
- Double-sealed, nitrogen-purged HDPE containers inside fiber drums to maintain an inert atmosphere.
- Storage and shipment under refrigerated conditions (2–8°C) to maximize shelf-life and stability.
- Full regulatory support, including Safety Data Sheets (SDS), TSE/BSE statements, and country-specific import documentation.
This integrated approach—from a high-fidelity manufacturing process to validated analytics and secure logistics—ensures that customers receive a reliable, high-performance organoboron compound that meets the exacting demands of modern pharmaceutical development. For partners requiring a dependable source of this key Suzuki Coupling Reagent, NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier global supplier with the technical expertise and scale to support commercial API production.